MEDIGEN VACCINE BIOLOGICS CORP. A Phase II, Prospective, Double-blinded, Multi-Center, Multi-Regional Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901. [s.l.]: [s.n.] Dostupné online. Submitted: December 31, 2020.
MEDIGEN VACCINE BIOLOGICS CORP. A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901. [s.l.]: [s.n.] Dostupné online. Submitted: July 22, 2020.
MEDIGEN VACCINE BIOLOGICS CORP. A Phase II, Prospective, Randomized, Double-Blind, Dose-Comparison, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901 in Elderly Adults. [s.l.]: [s.n.] Dostupné online. Submitted: March 25, 2021.
MEDIGEN VACCINE BIOLOGICS CORP. A Phase II, Prospective, Double-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS CoV 2 Vaccine Candidate MVC COV1901 in Adolescents. [s.l.]: [s.n.] Dostupné online. Submitted: June 30, 2021.
HSIEH, Szu-Min; LIU, Wang-Da; HUANG, Yu-Shan. Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. EClinicalMedicine. 2021-08, roč. 38, s. 100989. PMID: 34222848
PMCID: PMC8233066. Dostupné online [cit. 2021-11-16]. ISSN2589-5370. DOI10.1016/j.eclinm.2021.100989. PMID34222848.
globenewswire.com
CORPORATION, Dynavax Technologies. Dynavax and Medigen Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Vaccine Candidate. GlobeNewswire News Room [online]. 2020-07-23 [cit. 2021-11-16]. Dostupné online. (anglicky)
medigenvac.com
Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax’s CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan. www.medigenvac.com [online]. [cit. 2021-11-16]. Dostupné online.
Medigen Collaborates with Dynavax to Develop Novel Adjuvanted COVID-19 Vaccine Candidate. www.medigenvac.com [online]. [cit. 2021-11-16]. Dostupné online.
MVC and NIH Collaborate to Develop COVID-19 Vaccine. www.medigenvac.com [online]. [cit. 2021-11-16]. Dostupné online.
Medigen’s COVID-19 Vaccine Combined with Dynavax’s CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October. www.medigenvac.com [online]. [cit. 2021-11-16]. Dostupné online.
MVC Signed an License Agreement with NIH on COVID-19 Vaccine. www.medigenvac.com [online]. [cit. 2021-11-16]. Dostupné v archivu pořízeném dne 2021-11-16.
MVC COVID-19 Vaccine Obtains Taiwan EUA Approval. www.medigenvac.com [online]. [cit. 2021-11-16]. Dostupné v archivu pořízeném dne 2021-10-09.
worldcat.org
HSIEH, Szu-Min; LIU, Wang-Da; HUANG, Yu-Shan. Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. EClinicalMedicine. 2021-08, roč. 38, s. 100989. PMID: 34222848
PMCID: PMC8233066. Dostupné online [cit. 2021-11-16]. ISSN2589-5370. DOI10.1016/j.eclinm.2021.100989. PMID34222848.
